Other · developed by Regeneron Pharmaceuticals
ALN-PNP is an investigational agent studied in metabolic dysfunction-associated steatotic liver disease (MASLD).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07527910 | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Updated Nov 22, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →